Thomas Brock's 1966 discovery of Thermus aquaticus in Yellowstone's hot springs gave molecular biology a heat-stable enzyme, made PCR practical and changed medicine, forensics and genetics forever.
Taq polymerase is a very thermostable DNA polymerase, extracted from the bacterium Thermus aquaticus. Its function in the Polymerase Chain Reaction (PCR) is similar to that of cellular DNA polymerases, synthesizing new DNA strands using an existing DNA template. The difference is that the DNA is synthesized at temperatures, which will instantly destroy any ordinary enzyme.
The Polymerase Chain Reaction involves three stages of heating: 95°C for the denaturation phase, 55°C for the annealing stage, and 72°C for the synthesis of the DNA strand. The main challenge lies in the first phase, because disassembling the double strands of the molecule requires temperature, which destroys the majority of enzymes. Before the discovery of Taq, scientists had to manually add fresh DNA polymerase after every denaturation cycle, making automation impractical.
However, Taq polymerase was able to solve this problem completely. It works at 72°C and survives heating to 95°C without any loss of activity. This made it possible to create PCR machines instead of conducting experiments manually.
The scientific consensus of the early 1960s was that, nothing biologically meaningful survived above 50°C. Thomas D. Brock was sceptical. A microbiologist at Indiana University, he began sampling the microbial mats growing along the edges of Yellowstone's hot springs during fieldwork in 1964 and 1966, places like Mushroom Spring and the Grand Prismatic, where water temperatures held steady above 70°C.
The mats were very much alive. At the time, many microbiologists believed temperatures above 50°C were incompatible with complex biological activity. Working with graduate student Hudson Freeze, Brock isolated a previously undescribed bacterium from those boiling margins and named it Thermus aquaticus, literally, "hot water." The discovery itself was significant. What Brock did next was transformative: in 1969, he deposited the cultures with the American Type Culture Collection (ATCC), placing them in the public scientific commons. No patent. No restriction. Any researcher who wanted T. aquaticus could simply request it. That decision, made without any awareness of what the bacterium would eventually enable, is the quiet hinge on which the entire PCR story turns.
The thermostable polymerase inside T. aquaticus was first characterised by Chien et al. in a 1976 paper in the Journal of Bacteriology. Interesting biochemistry, at the time, but there was no way of using it for everyday experiments. In 1983, Kary Mullis at Cetus Corporation developed the concept for PCR. His early experiments used the Klenow fragment of E. coli DNA polymerase I, which denatures at high temperatures. Technicians had to pause each cycle, add fresh enzymes by hand, then continue. The process was tedious enough that PCR remained a niche technique.
Early PCR experiments often required researchers to remain beside the apparatus for hours, repeatedly opening reaction tubes to replenish heat-sensitive polymerase after each cycle.
Researchers at Cetus recognized that the thermostable polymerase from Thermus aquaticus could solve PCR's biggest technical limitation. In 1988, Saiki, Gelfand, and colleagues at Cetus published their landmark paper in Science describing what happened when they substituted Taq polymerase into the reaction. The enzyme held through every denaturation step. The entire reaction now ran unattended inside a thermal cycler. Mullis won the Nobel Prize in Chemistry in 1993 for the PCR concept. Although Kary Mullis received the 1993 Nobel Prize in Chemistry for developing PCR, Brock's earlier discovery of Thermus aquaticus provided the essential enzyme that made routine PCR practical.
Taq polymerase has made that concept clinically real.
The downstream consequences of Taq-enabled PCR are many. Forensic DNA fingerprinting requires amplifying degraded, trace-quantity DNA from crime scenes, for which PCR became a reliable tool. HIV viral load monitoring, hepatitis B and C genotyping, and same-day bacterial identification all depend on PCR workflows that are built around thermostable polymerases.
India's encounter with this at scale came in 2020. When SARS-CoV-2 arrived, the Indian Council of Medical Research (ICMR) mandated RT-PCR as the diagnostic reference standard, requiring dual-target confirmation to reduce false negatives. Millions of tests ran through NABL-accredited laboratories on Taq-based reagent kits, a significant proportion manufactured domestically. Prenatal diagnosis has also shifted: PCR-based detection of chromosomal anomalies and single-gene disorders now informs clinical decisions in foetal medicine units at tertiary centres across the country.
Cetus Corporation filed its Taq polymerase patent in 1989. Two years later, Hoffmann-La Roche acquired the PCR rights for approximately USD 300 million. The bacterium Brock had freely deposited into a public collection, collected from a public national park, had become one of the most commercially lucrative biological materials in modern history. Neither Thomas Brock nor Yellowstone saw any of that revenue.
The ethical discomfort this generated eventually produced a policy response. In 1997, Yellowstone National Park signed a benefit-sharing agreement with Diversa Corporation, one of the earliest formal frameworks acknowledging that commercially valuable biological resources from public ecosystems carry obligations to those ecosystems.
Such benefit-sharing agreements are intended to ensure that a portion of the benefits arising from the commercial use of biological resources is returned to support conservation, research, or public interests associated with the source environment.
For India, the Taq story is not merely a historical footnote. The Biological Diversity Act 2002 and India's commitments under the Nagoya Protocol on Access and Benefit Sharing were shaped, in part, by precisely these kinds of cases, where bioprospecting in common-pool environments generated private wealth without reciprocal benefit to the source. The Biological Diversity Act provides a legal framework for regulating access to biological resources and ensuring equitable sharing of benefits arising from their use. The Nagoya Protocol is an international agreement that establishes rules for fair and equitable sharing of benefits derived from genetic resources.
In most NABL-accredited diagnostic laboratories in India, Taq polymerase-based assays are performed. Of these, TB carries the highest volume of tests. The National Tuberculosis Elimination Program (NTEP) has deployed CBNAAT (Cartridge Based Nucleic Acid Amplification Test) and Truenat platforms to district-level facilities across the country, both of which use thermostable polymerase chemistry to return rifampicin resistance data within hours rather than weeks. ICMR's dual-target PCR guidelines apply here too, reinforcing accuracy at the point of maximum clinical consequence.
The footprint extends well beyond TB and now underpins a wide range of molecular diagnostics and genetic testing applications. Taq-based platforms are used in HPV genotyping for cervical cancer screening, TORCH panel diagnostics in high-risk pregnancies, HIV viral load monitoring at ART centres, and RT-PCR testing across multiple infectious disease workflows. After 2020, domestic manufacturers including Molbio Diagnostics and Transasia Bio-Medicals scaled production of Taq reagent kits substantially, reducing India's dependence on imported diagnostic inputs for an enzyme that now sits inside almost every molecular pathology report issued in the country.
Taq's thermal resilience comes with a structural compromise. It lacks 3'→5' exonuclease proofreading activity, meaning that when it inserts an incorrect nucleotide during DNA synthesis, it cannot detect and remove the error. The resulting mistake rate runs to roughly 1 misincorporation in every 9,000 nucleotides. For diagnostic PCR, where the result is presence or absence of a target sequence, that error rate is clinically acceptable. For applications where the exact nucleotide sequence matters, cloning, next-generation sequencing library preparation, site-directed mutagenesis, it is something to be noted.
The table below contrasts Taq with the high-fidelity alternatives used in sequence-critical work:
| Enzyme | Source Organism | Proofreading (3'→5') | Error Rate | Primary Use |
|---|---|---|---|---|
| Taq Polymerase | Thermus aquaticus | No | ~1 in 9,000 nt | Diagnostic PCR (TB, viral loads, genotyping) |
| Pfu Polymerase | Pyrococcus furiosus | Yes | Low | Cloning, high-fidelity amplification |
| Phusion / Q5 | Engineered/Recombinant | Yes | Ultra-low (up to 50x lower than Taq) | NGS library prep, site-directed mutagenesis |
Taq holds its ground in routine diagnostics because it is fast, inexpensive, and well-characterised across decades of clinical validation. High-fidelity enzymes enter the workflow only when the sequence itself, not merely its presence, is the clinically meaningful output.
More than half a century after Thomas Brock waded into a Yellowstone hot spring with a sample jar, the bacterium he brought back still drives molecular diagnosis in clinics that Brock himself could not have imagined. The thermal springs did not give up their secret, a scientist went looking for it, shared what he found, and the rest followed.
Thermus aquaticus thrives in boiling water, and the enzyme it produces powers every PCR test run today
Thomas Brock discovered it in Yellowstone in 1966 and shared it freely; Roche later sold the patent rights for USD 300 million
Taq polymerase survives 95°C, making automated PCR possible, before Taq, technicians added fresh enzyme by hand after every cycle
Limitation: no proofreading, so it makes errors, fine for diagnostics, not for sequencing
Brock, T. D., & Freeze, H. (1969). Thermus aquaticus gen. n. and sp. n., a nonsporulating extreme thermophile. Journal of Bacteriology, 98(1), 289–297. https://doi.org/10.1128/jb.98.1.289-297.1969
Chien, A., Edgar, D. B., & Trela, J. M. (1976). Deoxyribonucleic acid polymerase from the extreme thermophile Thermus aquaticus. Journal of Bacteriology, 127(3), 1550–1557. https://doi.org/10.1128/jb.127.3.1550-1557.1976
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239(4839), 487–491. https://doi.org/10.1126/science.2448875
World Health Organization. (2021). WHO consolidated guidelines on tuberculosis: Molecular diagnostics for tuberculosis. WHO. https://www.who.int/publications/i/item/9789240029415
Secretariat of the Convention on Biological Diversity. (2011). Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization.
https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf